Vistagen Therapeutics Downgraded to Hold by Maxim Group
AI Summary1 min read
TL;DR
Vistagen Therapeutics was downgraded from Buy to Hold by Maxim Group, with no price target change. The biotech firm focuses on psychiatric and neurological disorders, with an average one-year price target of $14.50, suggesting significant upside potential.
Tags
VistagenVistagen TherapeuticsMaxim Groupdowngradebiotechnologyprice target
Vistagen Therapeutics (VTGN) was downgraded from Buy to Hold by Maxim Group, with no changes to the price target. The firm is a biotechnology company focused on psychiatric and neurological disorders. The average one-year price target is $14.50, with a high estimate of $19.00 and a low estimate of $12.00, indicating a potential upside of 1,584.09% from the current price of $0.86.
